Revive Therapeutics Ltd.
RVV
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -45.50% | 105.15% | -67.34% | -19.92% | 79.99% |
| Depreciation & Amortization | -- | -100.00% | -100.00% | -100.00% | -100.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.99% | 42.16% | -75.64% | -64.16% | 52.21% |
| Operating Income | 59.99% | -42.16% | 75.64% | 64.16% | -52.21% |
| Income Before Tax | 40.94% | -267.12% | 71.03% | 54.01% | -18.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.94% | -267.12% | 71.03% | 54.01% | -18.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.94% | -267.12% | 71.03% | 54.01% | -18.96% |
| EBIT | 59.99% | -42.16% | 75.64% | 64.16% | -52.21% |
| EBITDA | 59.99% | -42.25% | 75.64% | 64.16% | -52.27% |
| EPS Basic | 37.50% | -264.44% | 72.22% | 62.50% | 0.00% |
| Normalized Basic EPS | 40.00% | 33.33% | 72.73% | 50.00% | 0.00% |
| EPS Diluted | 37.50% | -264.44% | 72.22% | 62.50% | 0.00% |
| Normalized Diluted EPS | 40.00% | 33.33% | 72.73% | 50.00% | 0.00% |
| Average Basic Shares Outstanding | 2.57% | 1.16% | 7.77% | 16.98% | 17.03% |
| Average Diluted Shares Outstanding | 2.57% | 1.16% | 7.77% | 16.98% | 17.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |